Publications by authors named "Graciela N Ciccia"

Article Synopsis
  • Desmopressin (dDAVP) is a synthetic form of vasopressin that helps reduce bleeding during surgery by increasing hemostatic factors like von Willebrand factor (vWF).
  • Previous studies in animals showed that dDAVP could inhibit metastasis and improve survival in cancer models.
  • A recent trial in breast cancer patients found that dDAVP was generally safe, reduced surgical bleeding, and improved vWF levels, indicating potential for future cancer treatment applications.
View Article and Find Full Text PDF

The synthetic nonapeptide 1‑desamino‑8‑D‑arginine vasopressin (dDAVP) can reduce tumor cell growth through agonist action on the vasopressin V2 receptor. A structure‑antiproliferative activity relationship analysis of dDAVP was performed using the alanine scanning technique on the aggressive MDA‑MB‑231 human breast carcinoma cell line. The results from this analysis demonstrated that the amino acids located at the loop of dDAVP are important for the antiproliferative activity of dDAVP, highlighting the key role of the N‑terminal region of the peptide in the interaction with the tumor cell surface receptor.

View Article and Find Full Text PDF

Background: Desmopressin (dDAVP), a synthetic nonapeptide derivative of arginine vasopressin, is a safe antidiuretic and hemostatic compound that acts as a selective agonist for the vasopressin V2 membrane receptor (V2R). It is known that dDAVP can inhibit progression of residual metastatic cells in preclinical models. Among other mechanisms, the compound induces an agonist effect on V2R present in tumor cells.

View Article and Find Full Text PDF